Open Access Highly Accessed Open Badges Research article

Interleukin-6 regulates anti-arthritic effect of methotrexate via reduction of SLC19A1 expression in a mouse arthritis model

Misato Hashizume1*, Hiroto Yoshida1, Keisuke Tanaka1, Miho Suzuki1, Isao Matsumoto2, Takayuki Sumida2 and Masahiko Mihara1

Author Affiliations

1 Product Research Department, Fuji-Gotemba Research Laboratories, Chugai Pharmaceutical Co., Ltd., 1-135 Komakado, Gotemba, Shizuoka, 412-8513, Japan

2 Division of Clinical Immunology, Doctoral Program in Clinical Science, Graduate School of Comprehensive Human Sciences, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8575, Japan

For all author emails, please log on.

Arthritis Research & Therapy 2012, 14:R96  doi:10.1186/ar3821

Published: 30 April 2012

Additional files

Additional file 1:

A figure showing mRNA expression for multidrug resistance protein (MRP-1) and breast cancer resistance protein (BCRP). Synoviocytes from arthritic mice were cultured for 24 h with interleukin-6 (IL-6) (1, 10, 100 ng/mL) + soluble IL-6 receptor (sIL-6R) (100 ng/mL) or methotrexate (1, 10, 100 nM). After culturing, cell lysate was collected and mRNA expression for (A) MRP-1 and (B) BCRP was measured by real-time polymerase chain reaction. Each column and vertical line represents the mean and standard deviation of triplicate cultures. Statistical significance was analyzed by Dunnett's multiple comparison test or the unpaired t-test. GAPDH, glyceraldehyde-3-phosphate dehydrogenase.

Format: DOC Size: 54KB Download file

This file can be viewed with: Microsoft Word Viewer

Open Data